Mountain Valley MD Holdings Inc looking to eradicate needles with its patented Quicksome oral drug delivery technology proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
Mountain Valley MD Pursues Ambitious Initiatives, Including Partnership With FDA Monday, July 12, 2021 1:16 AM UTC
The COVID-19 pandemic has put the spotlight squarely on medical, pharmaceutical and biotechnology companies that work to create solutions for these medical issues. One standout in this field is Mountain Valley MD (MVMD), which has recently announced a number of important initiatives to help in the treatment of a variety of illnesses and medical conditions. The International Business Times recently published an article exploring the many ambitious projects currently underway at MVMD and praising the company for its many accomplishments.
MVMD was founded in 2018 and has rapidly risen to the top of the biotechnology field thanks to its innovative approaches to some of the most challenging issues facing the medical community today. The company has created a number of proprietary solutions that have made it
Other highlights from Mountain Valley MD s trial portfolio include:
A recent Bio Safety Level 4 lab study of coronavirus (COVID-19) viral clearance in transgenic mice is expected to deliver results early next week
It has filed the Porous Aluminum Nano-Structured Adjuvant patent to support its advanced vaccine dose sparing work, with results from the associated study expected in late May or early June
Husbandry animal trials have started in Canada and Bangladesh to validate the superiority of its injectable solubilized Ivermectin technology, Ivectosol 1%, versus current commercially available forms to treat a broad category of animal parasites, with results from both studies expected in June
Mountain Valley MD says it has filed a novel cancer adjuvant patent and is proceeding with pre-clinical trials
The company said the cancer patent has been filed for direct intratumoral injection, intravenously, infusions or instillations as adjuvants for broad chemotherapeutic to immunotherapeutic cancer regimens Mountain Valley MD said it believes the research will have near-immediate application to direct human trials based on safety and efficacy of ivermectin
Mountain Valley MD Holdings Inc. (CSE:MVMD) (FRA:20MP) (OTCQB:MVMDF) announced that it has filed a novel cancer adjuvant patent and is proceeding with pre-clinical trials with third-party cancer Contract Research Organizations (CROs) in triple-negative breast cancer, metastatic melanoma, and lung carcinoma.
GameSquare Esports Inc (CSE:GSQ) (FRA:29Q1), through its Gaming Community Network (GCN) division, has signed a sales partnership with Even Matchup Gaming (EMG). The company said EMG owns and operates major esports events, including Get On My Level, the largest fighting game tournament in Canada, and Let s Make Moves, the largest Super Smash Bros event in the New York area. “We see a lot of potential in helping EMG’s team maximize their sales pipeline,” said Justin Kenna, CEO of GameSquare, in a statement.
Mydecine Innovations Group Inc (NEO:MYCO) (OTCMKTS:MYCOF) (FRA:0NFA) has announced a partnership with LeadGen Labs, a custom synthesis and contract research organization, to support Mydecine’s novel psychedelic drug development efforts and increase the number of novel molecules the company can synthesize concurrently. Following the announcement of the company’s four initial drug candidates, the Denver-based company said it and LeadGen Labs will work to synthesize no